Michael J. Gelfand, MD

Academic Affiliations

Professor, UC Department of Radiology

UC Department of Pediatrics

Phone 513-636-7650

Fax 513-636-8145


Nuclear medicine

Michael J. Gelfand, MD, received his BA from the University of Michigan and his MD from Stanford University. After two years at the National Institutes of Health, he completed residencies in pediatrics at Cincinnati Children's and nuclear medicine at the University of Cincinnati Medical Center.

Dr. Gelfand's research interests include I-123-MIBG imaging of neuroblastoma, new applications of hybrid imaging (PET/CT, SPECT/CT, PET/MRI) in pediatrics, and radiation dose reduction in nuclear medicine and hybrid imaging.

Dr. Gelfand has served as president of the Society of Nuclear Medicine, and served on the board of directors of that organization for 10 years.

Dr. Gelfand co-edited the textbooks Effective Use of Computers in Nuclear Medicine and Pediatric Nuclear Imaging. His publications include 126 journal articles and 31 book chapters. He has been an invited lecturer or visiting professor in France, Germany, the Netherlands, Italy, Argentina, Brazil, Japan and Australia.

BA: University of Michigan, Ann Arbor, MI, 1966.

MD: Stanford University, Stanford, CA, 1971.

Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1973-1975, 1977; Nuclear Medicine, University of Cincinnati, Cincinnati, OH, 1975-1977.

Certification: Pediatrics, 1978; Nuclear Medicine, 1978.

View PubMed Publications

Gelfand MJ, Parisi MT, Treves ST. Pediatric Radiopharmaceutical Administered Doses: 2010 North American Consensus Guidelines. J Nucl Med. 2011 Jan 13.

Seo JH, Holland K, Rose D, Rozhkov L, Fujiwara H, Byars A, Arthur T, Degrauw T, Leach JL, Gelfand MJ, Miles L, Mangano FT, Horn P, Lee KH. Multimodality imaging in the surgical treatment of children with nonlesional epilepsy. Neurology. 2011 Jan 4;76(1):41-8.

Wagner LM, Gelfand MJ, Laor T, Ryckman FC, Al-Ghawi H, Bove KE. A Welcome Surprise: Nodular Fasciitis Presenting as Soft Tissue Sarcoma. J Pediatr Hematol Oncol. 2010 Oct 21.

Gelfand MJ. Dose reduction in pediatric hybrid and planar imaging. Q J Nucl Med Mol Imaging. 2010 Aug;54(4):379-88.

Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009 Aug;50(8):1237-43.

Young LR, Franz DN, Nagarkatte P, Fletcher CD, Wikenheiser-Brokamp KA, Galsky MD, Corbridge TC, Lam AP, Gelfand MJ, McCormack FX. Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest. 2009 Sep;136(3):926-33.

Gelfand MJ. Dosimetry of FDG PET/CT and other molecular imaging applications in pediatric patients. Pediatr Radiol. 2009 Feb;39 Suppl 1:S46-56

Gelfand MJ, Gruppo RA, Nasser MP. Ventilation-perfusion scintigraphy in children and adolescents is associated with a low rate of indeterminate studies. Clin Nucl Med. 2008 Sep;33(9):606-9.

Gelfand MJ, Lemen LC. PET/CT and SPECT/CT dosimetry in children: the challenge to the pediatric imager. Semin Nucl Med. 2007 Sep;37(5):391-8. Review.

Wu SW, Graham B, Gelfand MJ, Gruppo RE, Dinopolous A, Gilbert DL. Clinical and positron emission tomography findings of chorea associated with primary antiphospholipid antibody syndrome. Mov Disord. 2007 Sep 15;22(12):1813-5.